A Phase II Study Of Pegylated Liposomal Doxorubicin (Doxil) In Combination With Rituxan, Cyclophosphamide, Vincristine and Prednisone (DR-COP) In Newly Diagnosed Aggressive Non-Hodgkin's Lymphomas

Inclusion Criteria:

- Pathologic diagnosis of Non-Hodgkin's lymphoma of B-cell origin: follicular large
cell, diffuse large cell (including all B-cell variants), Burkitt or Burkitt-like
lymphoma

- All stages of disease

- Measurable or evaluable tumor parameter(s)

- Age greater than 17 years old

- Karnofsky performance status greater or equal to 50%

- AGC greater or equal to 1.0; platelets greater or equal to 75,000(unless abnormal
because of lymphoma)

- Bilirubin less or equal to 2.0; SGOT less or equal to 3 times upper limit of normal
(unless abnormal because of lymphoma)

- Creatinine less or equal to 2.0 or creatinine clearance greater or equal to 60 ml/min
(unless abnormal because of lymphoma)

- LVEF greater or equal to 45%

- Concurrent RT with or without steroids for emergency conditions secondary to lymphoma
(i.e., CNS tumor, cord compression)are permitted

- Men and women of childbearing potential must agree to use adequate birth control for
the duration of the therapy and for 3 months after completion of therapy

- Signed informed consent

Exclusion Criteria:

- Prior systemic cytotoxic therapy or RT for lymphoma

- Second active tumor, other than non-melanomatous skin ca and in-situ cervical cancer

- HIV seropositive

- Primary CNS lymphoma

- Pregnant or nursing women

- Unable to comply with the requirements of the protocol, or unable to provide adequate
informed consent, in the opinion of the PI